MicroRNA-4651 targets bromodomain-containing protein 4 to inhibit non-small cell lung cancer cell progression

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• Bromodomain-containing protein 4 (BRD4) is overexpressed in non-small cell lung cancer (NSCLC), promoting tumor progression.
• Identifying regulatory mechanisms of BRD4 is crucial for NSCLC therapeutic strategies.

Purpose of the Study:

• To investigate the role of microRNA-4651 (miR-4651) in regulating BRD4 expression and its functional impact on NSCLC.
• To explore the therapeutic potential of targeting the miR-4651/BRD4 axis in NSCLC.

Main Methods:

• RNA pull-down assays to confirm direct binding of miR-4651 to BRD4 mRNA.
• Luciferase reporter assays to assess the regulatory effect of miR-4651 on BRD4 3'-UTR.
• In vitro cell proliferation, migration assays, and in vivo xenograft models in immunodeficient mice.
• Analysis of miR-4651 and BRD4 expression in human NSCLC tissues.

Main Results:

• miR-4651 directly targets and negatively regulates BRD4 expression in NSCLC cells.
• Overexpression of miR-4651 suppressed NSCLC cell growth, proliferation, and migration, while inhibition enhanced these processes.
• BRD4 re-expression reversed the inhibitory effects of miR-4651, confirming BRD4 as the key target.
• miR-4651 overexpression led to reduced tumor growth in vivo.
• miR-4651 was downregulated in human NSCLC tissues, inversely correlating with BRD4 levels.

Conclusions:

• miR-4651 acts as a tumor suppressor in NSCLC by targeting BRD4.
• The miR-4651/BRD4 pathway represents a promising therapeutic target for NSCLC treatment.
• Restoring miR-4651 levels could offer a novel strategy for combating NSCLC progression.